The PD-L1 expression is determined by the LifeTracDx® blood test, which captures Circulating Tumor Cells (CTCs) and Cancer Associated Macrophage-Like cells (CAMLs) by staining the cells for PD-L1 ...

Summit Therapeutics' shares dropped 36% after ivonescimab data showed no significant survival benefit. Click to read if SMMT ...

Merck (NYSE:MRK) shares inched higher on Friday after Summit Therapeutics (NASDAQ:SMMT) announced the latest survival data ...

Summit Therapeutics (SMMT) noted that Akeso (AKESF) announced ivonescimab was approved by the Chinese Health Authorities for a second ...

A new study published in AI in Precision Oncology examines the ability of large language models (LLMs) to rapidly extract PD-L1 biomarker details from an electronic health record (EHR). PD-L1 ...

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.

Unlike Opdivo, Keytruda’s European licence stipulates a PD-L1 test must be conducted in previously treated patients - anyone with expression of the biomarker of ≥1% could be eligible for ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

SANTA CLARA, Calif. - Agilent Technologies Inc. (NYSE: A), a $29.3 billion market cap company with a robust 54% gross profit margin, has announced that its PD-L1 IHC 22C3 pharmDx assay has received ...

SANTA CLARA, Calif. - Agilent Technologies Inc. (NYSE: A), a $29.3 billion market cap company with a robust 54% gross profit margin, has announced that its PD-L1 IHC 22C3 pharmDx assay has ...